Company Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors.

The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics Inc.

Country	United States
Founded	2015
IPO Date	Oct 20, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	15
CEO	Martin Lehr

Contact Details

Address: 2001 Market Street, Suite 3915 Philadelphia, Pennsylvania 19103 United States
Phone	267 225 7416
Website	contexttherapeutics.com

Stock Details

Ticker Symbol	CNTX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$5.00
CIK Code	1842952
CUSIP Number	21077P108
ISIN Number	US21077P1084
Employer ID	86-3738787
SIC Code	2834

Key Executives

Name	Position
Martin A. Lehr	Co-Founder, President, Chief Executive Officer and Director
Jennifer Minai-Azary	Chief Financial Officer and Treasurer
Alex C. Levit Esq., J.D.	Chief Legal Officer and Corporate Secretary
Christopher Beck M.B.A.	Senior Vice President of Operations
Jeffrey Liebman	Associate Director of Accounting
Jennifer Dashnau M.B.A., Ph.D.	Senior Vice President of Technical Operations
Dr. Karen Chagin M.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Aug 5, 2026	8-K	Current Report
Aug 5, 2026	10-Q	Quarterly Report
Jul 31, 2026	8-K	Current Report
Jul 31, 2026	SCHEDULE 13G/A	Filing
Jul 27, 2026	SCHEDULE 13G	Filing
Jun 26, 2026	8-K	Current Report
Jun 15, 2026	8-K	Current Report
May 18, 2026	8-K	Current Report
May 15, 2026	SCHEDULE 13G/A	Filing
May 14, 2026	SCHEDULE 13G/A	Filing

View All SEC Filings